Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nabilone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabilone SCHEMBL33339 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL17223864 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29475614 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL11268571 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL2762240 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL563809 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL13759779 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615666 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL15520922 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615083 | 0.99 | CNR2 (0.98) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204419-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| US-20260083161-A1 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS | NATURAL EXTRACTION SYS LLC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12150928-B2 | Methods of treating sarin exposure with tetrahydrocannabinol and cannabidiol combinations | KOTZKER CONSULTING LLC (US) | 2024-11-26 | — | — | US | disclosed |
| US-11964956-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240041761-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-02-08 | — | — | US | disclosed |
| US-20230241085-A1 | CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USE | APIRX PHARMACEUTICAL USA, LLC (US) | 2023-08-03 | — | — | US | disclosed |
| EP-3793517-B1 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2023-04-19 | — | — | EP | disclosed |
| US-20230050166-A1 | METHOD TO TREAT VITILIGO | APIRX PHARMACEUTICAL USA, LLC (US) | 2023-02-16 | — | — | US | disclosed |
| CN-115605195-A | Methods and compositions for treating cannabis use disorders and alleviating cannabinoid withdrawal | 普利欧制药有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4114379-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | Pleopharma, L.L.C. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220370650-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11484510-B2 | Method to treat vitiligo | APIRX PHARMACEUTICAL USA, LLC (US) | 2022-11-01 | — | — | US | disclosed |
| WO-2022204419-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964956-B2 | Cannabinergic compounds and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885NR1I2 1577/4885 |
| US-20240041761-A1 | Pharmaceutical Formulation | ALG1, MCOLN1, MCOLN3 | CNR1 4/4885CNR2 6/4885NR1I2 4474/4885 |
| US-12150928-B2 | Methods of treating sarin exposure with tetrahydrocannabinol and cannabidiol combinations | CNR2, BCHE, CNR1 | CNR1 3/4885CNR2 1/4885NR1I2 330/4885 |
| US-20230050166-A1 | METHOD TO TREAT VITILIGO | CNR2, LPCAT3, CNR1 | CNR1 3/4885CNR2 1/4885NR1I2 2133/4885 |
| US-20260083161-A1 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS | CNR2, CNR1, OPRD1 | CNR1 2/4885CNR2 1/4885NR1I2 3129/4885 |
| US-11484510-B2 | Method to treat vitiligo | CNR2, LPCAT3, CNR1 | CNR1 3/4885CNR2 1/4885NR1I2 2133/4885 |
| US-20220370650-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | ADA, SLC29A1, SLC29A2 | CNR1 4154/4885CNR2 4580/4885NR1I2 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.